Clonaid
Clonaid
Clonaid is a controversial biotechnology company that gained global attention for its claims of successfully cloning a human being. The company was founded in 1997 by the Raelian religious group, which believes that extraterrestrial beings created life on Earth. Clonaid's announcement of the birth of the first cloned human, named Eve, in 2002 sparked ethical debates and legal challenges.
History[edit]
Clonaid was established in 1997 by the Raelian leader Claude Vorilhon, also known as Rael. The company's goal was to advance human cloning technology and offer cloning services to individuals seeking to replicate themselves or loved ones. Clonaid's controversial activities attracted scrutiny from governments, scientific communities, and ethicists worldwide.
Cloning Controversy[edit]
In December 2002, Clonaid made headlines by claiming to have successfully cloned a human being. The announcement of baby Eve's birth raised ethical concerns about the implications of human cloning and the potential for exploitation. Many countries, including the United States, imposed bans on human cloning in response to Clonaid's actions.
Legal Challenges[edit]
Clonaid faced legal challenges and investigations in various countries following its claims of human cloning. Authorities questioned the company's scientific credibility and adherence to ethical standards in conducting cloning experiments. The legal battles surrounding Clonaid's activities highlighted the complex regulatory landscape governing biotechnological advancements.
Legacy[edit]
Despite the controversy and skepticism surrounding its claims, Clonaid remains a prominent figure in the history of biotechnology and bioethics. The company's pursuit of human cloning technology raised important questions about the boundaries of scientific innovation and the ethical considerations of manipulating human life.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian